Shane: The swelling agents we are seeing these daze are finely engineered components.
This oily gaak that is riding along is a tough cookie to crack.
This is why I say multiple solvent....multiple steps.
To this day, Ibee has never ever employed a front side A/B because all his experimentation was geared toward near maximum yield of clean Pfed.
There have been many times in the past that after a new formulation hit the shelves, the solventwash/alky extracts that Ibee's accustomed to, would produce the yield but the pfed would be gaaked. These gaaks were narrowed down to encapsulating agents that hitched a ride. Some solvent washes always seemed to rid them.
This brings us to the swelling agents they employ in some pills.
Geez is absolutely right when he says you'll by one particular OTC brand at one store and it will produce nice yield and clean feedstock by employing a known effective extraction method.
You go to another store and buy what's in stock...different brand....different formulation and you're screwed before you get past the middle mark of the process and end up with pfed that's iffy.
When the pfeds iffy, it's nowares good enough and in the process of cleaning it up, you lose a large part of the expected to mechanical loses and stuck on glass demons!
It wasn't long ago that a newly contributed method would work in kentucky and the same method would work in washington state.
Today we are lucky to have a method work for two bees in the same state in the same month.
If you want Ibee's assessment of what's causing this, They have shifted what's included in the individual packages.
Forget trying to run redhots and white 60's in the same extraction batch. Forget trying to run 120's and 60's in the same extraction batch. You'll bee doomed from the start.
This was difficult to do with bulk extraction since the first Orange Gaak hitthe shelves. But it could be done if the orange gaak was isolated and precipitated out before moving on.
It helps to read excerps from patents to understand some of what's taking place concernng encapsulating agents or swelling agents and other prefered inactive ingredients.
If you can get an understanding of what they do and how they act in the formulation, you're that much closer to understanding what may be employed as a viable approach toward effecting their removal.
The encapsulated product may generally be used at the desired level, the amount being dependent upon the amount of active agent to be incorporated, the desired hardness of the tablet, and the oxidative resistance desired. In general, the encapsulated product will be used in an amount of from about 1 to about 95% by weight of the tablet allowing for the active agent to be incorporated in an amount of from about 1 to about 60, particularly from about 10 to about 50%, by weight of the tablet.
The encapsulated product is particularly useful in a compressed tablet. The compressed tablet may be made using any method known in the art, particularly by direct compression of the tablet components. In the alternative, the tablet may be prepared by dry blending the encapsulated product with the other components of the formulation, granulating the mixture such as by fluid bed technology, roller compactor, extrusion, or high shear granulator, and dry compacting to a tablet.
Pharmaceutical excipients known in the art may be added to the pharmaceutical dosage form to impart satisfactory processing, compression, and disintegration characteristics to the formulation. Such excipients include, but are not limited to, diluents, flow enhancer, binders, lubricants and glidants, disintegrants, colors, flavors and sweetening agents. These excipients are well known in the art and are limited only by compatibility and characteristics desired.
Binders for the present invention include gelatin, microcrystalline cellulose, sugars, carboxymethyl cellulose, methyl cellulose, polyvinyl pyrrolidone, acacia, alginic acid, guar gum, hydroxypropyl methylcellulose, polyethylene oxide and ethyl cellulose.
Lubricants and glidants include talc, magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, vegetable oil, zinc stearate, and silicon dioxide.
Disintegrants suitable for the present invention include starches, algins, gums, croscarmelose, crospovidone, sodium starch glycolate, sodium laurel sulfate, microcrystalline cellulose, polacrilin potassium, and methylcellulose.
Diluents suitable for the present invention include dicalcium phosphate, calcium sulfate, lactose, cellulose, Kaolin, mannitol, sodium chloride, starch, sugars, calcium carbonate, calcium phosphate, dextrates, dextrin, dextrose, fructose, sorbitol, sucrose, and microcrystalline cellulose.
In particular, a binder is added to the tablet formulation to provide a tablet with the desired hardness. In general the hardness of the resultant tablet is at least about 3, more particularly at least about 4, most particularly at least about 6 kilopascals (kP).
If the final desired product is other than a pharmaceutical dosage form, alternative additives known to those arts may be present. For example, flavors and fragrances in a bath oil tablet or surfactants in a detergent tablet.
Upon contact with water, the moisture triggers the release mechanism, allowing the active agent to be released from the encapsulating starch. For example, upon digestion of the pharmaceutical dosage forms, the active agent is released to the body.
Geez: You touched on some points I was trying to make in the above post.
And I agree that a bee should have an arsenal of extraction methods today to choose from because what works on one pill is not gauranteed to work on the next pill.
The same holds true for "What works today, May Not work Tomorrow"
